Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

UNITED THERAPEUTICS (UTHR) Gross Margin: 2009-2025

Historic Gross Margin for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to 87.38%.

  • UNITED THERAPEUTICS's Gross Margin fell 152.00% to 87.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 116.47%, marking a year-over-year increase of 2753.00%. This contributed to the annual value of 89.24% for FY2024, which is 30.00% up from last year.
  • UNITED THERAPEUTICS's Gross Margin amounted to 87.38% in Q3 2025, which was down 1.85% from 89.03% recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Gross Margin high stood at 94.39% for Q1 2022, and its period low was 87.38% during Q3 2025.
  • Over the past 3 years, UNITED THERAPEUTICS's median Gross Margin value was 88.97% (recorded in 2024), while the average stood at 88.79%.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Gross Margin spiked by 197bps in 2022 and then tumbled by 471bps in 2023.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Gross Margin stood at 91.67% in 2021, then tumbled by 363bps to 88.04% in 2022, then surged by 41bps to 88.45% in 2023, then soared by 41bps to 88.90% in 2024, then tumbled by 152bps to 87.38% in 2025.
  • Its Gross Margin stands at 87.38% for Q3 2025, versus 89.03% for Q2 2025 and 88.36% for Q1 2025.